HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens

Lisa K. Poppe, Catherine Chunda-Liyoka, Eun H. Kwon, Clement Gondwe, John T West, Chipepo Kankasa, Clement B. Ndongmo, Charles Wood

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: The objectives of this study were to determine HIV drug resistance (HIVDR) prevalence in Zambian infants upon diagnosis, and to determine how changing prevention of mother-to-child transmission (PMTCT) drug regimens affect drug resistance. Design: Dried blood spot (DBS) samples from infants in the Lusaka District of Zambia, obtained during routine diagnostic screening, were collected during four different years representing three different PMTCT drug treatment regimens. Methods: DNA extracted from dried blood spot samples was used to sequence a 1493 bp region of the reverse transcriptase gene. Sequences were analyzed via the Stanford HIVDRdatabase (http://hivdb.standford.edu) to screen for resistance mutations. Results: HIVDR in infants increased from 21.5 in 2007/2009 to 40.2% in 2014. Nonnucleoside reverse transcriptase inhibitor resistance increased steadily over the sampling period, whereas nucleoside reverse transcriptase inhibitor resistance and dual class resistance both increased more than threefold in 2014. Analysis of drug resistance scores in each group revealed increasing strength of resistance over time. In 2014, children with reported PMTCT exposure, defined as infant prophylaxis and/or maternal treatment, showed a higher prevalence and strength of resistance compared to those with no reported exposure. Conclusion: HIVDR is on the rise in Zambia and presents a serious problem for the successful lifelong treatment of HIV-infected children. PMTCT affects both the prevalence and strength of resistance and further research is needed to determine how to mitigate its role leading to resistance.

Original languageEnglish (US)
Pages (from-to)1885-1889
Number of pages5
JournalAIDS
Volume31
Issue number13
DOIs
StatePublished - Aug 24 2017

Fingerprint

Drug Resistance
Mothers
HIV
Zambia
Reverse Transcriptase Inhibitors
RNA-Directed DNA Polymerase
Nucleosides
Pharmaceutical Preparations
Therapeutics
Mutation
DNA
Research
Genes

Keywords

  • Africa
  • HIV drug resistance
  • Zambia
  • antiretroviral therapy
  • prevention of mother-to-child transmission

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. / Poppe, Lisa K.; Chunda-Liyoka, Catherine; Kwon, Eun H.; Gondwe, Clement; West, John T; Kankasa, Chipepo; Ndongmo, Clement B.; Wood, Charles.

In: AIDS, Vol. 31, No. 13, 24.08.2017, p. 1885-1889.

Research output: Contribution to journalArticle

Poppe, LK, Chunda-Liyoka, C, Kwon, EH, Gondwe, C, West, JT, Kankasa, C, Ndongmo, CB & Wood, C 2017, 'HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens', AIDS, vol. 31, no. 13, pp. 1885-1889. https://doi.org/10.1097/QAD.0000000000001569
Poppe, Lisa K. ; Chunda-Liyoka, Catherine ; Kwon, Eun H. ; Gondwe, Clement ; West, John T ; Kankasa, Chipepo ; Ndongmo, Clement B. ; Wood, Charles. / HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. In: AIDS. 2017 ; Vol. 31, No. 13. pp. 1885-1889.
@article{4a16903a7a4048528007f26ecbdff1bf,
title = "HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens",
abstract = "Objectives: The objectives of this study were to determine HIV drug resistance (HIVDR) prevalence in Zambian infants upon diagnosis, and to determine how changing prevention of mother-to-child transmission (PMTCT) drug regimens affect drug resistance. Design: Dried blood spot (DBS) samples from infants in the Lusaka District of Zambia, obtained during routine diagnostic screening, were collected during four different years representing three different PMTCT drug treatment regimens. Methods: DNA extracted from dried blood spot samples was used to sequence a 1493 bp region of the reverse transcriptase gene. Sequences were analyzed via the Stanford HIVDRdatabase (http://hivdb.standford.edu) to screen for resistance mutations. Results: HIVDR in infants increased from 21.5 in 2007/2009 to 40.2{\%} in 2014. Nonnucleoside reverse transcriptase inhibitor resistance increased steadily over the sampling period, whereas nucleoside reverse transcriptase inhibitor resistance and dual class resistance both increased more than threefold in 2014. Analysis of drug resistance scores in each group revealed increasing strength of resistance over time. In 2014, children with reported PMTCT exposure, defined as infant prophylaxis and/or maternal treatment, showed a higher prevalence and strength of resistance compared to those with no reported exposure. Conclusion: HIVDR is on the rise in Zambia and presents a serious problem for the successful lifelong treatment of HIV-infected children. PMTCT affects both the prevalence and strength of resistance and further research is needed to determine how to mitigate its role leading to resistance.",
keywords = "Africa, HIV drug resistance, Zambia, antiretroviral therapy, prevention of mother-to-child transmission",
author = "Poppe, {Lisa K.} and Catherine Chunda-Liyoka and Kwon, {Eun H.} and Clement Gondwe and West, {John T} and Chipepo Kankasa and Ndongmo, {Clement B.} and Charles Wood",
year = "2017",
month = "8",
day = "24",
doi = "10.1097/QAD.0000000000001569",
language = "English (US)",
volume = "31",
pages = "1885--1889",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens

AU - Poppe, Lisa K.

AU - Chunda-Liyoka, Catherine

AU - Kwon, Eun H.

AU - Gondwe, Clement

AU - West, John T

AU - Kankasa, Chipepo

AU - Ndongmo, Clement B.

AU - Wood, Charles

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Objectives: The objectives of this study were to determine HIV drug resistance (HIVDR) prevalence in Zambian infants upon diagnosis, and to determine how changing prevention of mother-to-child transmission (PMTCT) drug regimens affect drug resistance. Design: Dried blood spot (DBS) samples from infants in the Lusaka District of Zambia, obtained during routine diagnostic screening, were collected during four different years representing three different PMTCT drug treatment regimens. Methods: DNA extracted from dried blood spot samples was used to sequence a 1493 bp region of the reverse transcriptase gene. Sequences were analyzed via the Stanford HIVDRdatabase (http://hivdb.standford.edu) to screen for resistance mutations. Results: HIVDR in infants increased from 21.5 in 2007/2009 to 40.2% in 2014. Nonnucleoside reverse transcriptase inhibitor resistance increased steadily over the sampling period, whereas nucleoside reverse transcriptase inhibitor resistance and dual class resistance both increased more than threefold in 2014. Analysis of drug resistance scores in each group revealed increasing strength of resistance over time. In 2014, children with reported PMTCT exposure, defined as infant prophylaxis and/or maternal treatment, showed a higher prevalence and strength of resistance compared to those with no reported exposure. Conclusion: HIVDR is on the rise in Zambia and presents a serious problem for the successful lifelong treatment of HIV-infected children. PMTCT affects both the prevalence and strength of resistance and further research is needed to determine how to mitigate its role leading to resistance.

AB - Objectives: The objectives of this study were to determine HIV drug resistance (HIVDR) prevalence in Zambian infants upon diagnosis, and to determine how changing prevention of mother-to-child transmission (PMTCT) drug regimens affect drug resistance. Design: Dried blood spot (DBS) samples from infants in the Lusaka District of Zambia, obtained during routine diagnostic screening, were collected during four different years representing three different PMTCT drug treatment regimens. Methods: DNA extracted from dried blood spot samples was used to sequence a 1493 bp region of the reverse transcriptase gene. Sequences were analyzed via the Stanford HIVDRdatabase (http://hivdb.standford.edu) to screen for resistance mutations. Results: HIVDR in infants increased from 21.5 in 2007/2009 to 40.2% in 2014. Nonnucleoside reverse transcriptase inhibitor resistance increased steadily over the sampling period, whereas nucleoside reverse transcriptase inhibitor resistance and dual class resistance both increased more than threefold in 2014. Analysis of drug resistance scores in each group revealed increasing strength of resistance over time. In 2014, children with reported PMTCT exposure, defined as infant prophylaxis and/or maternal treatment, showed a higher prevalence and strength of resistance compared to those with no reported exposure. Conclusion: HIVDR is on the rise in Zambia and presents a serious problem for the successful lifelong treatment of HIV-infected children. PMTCT affects both the prevalence and strength of resistance and further research is needed to determine how to mitigate its role leading to resistance.

KW - Africa

KW - HIV drug resistance

KW - Zambia

KW - antiretroviral therapy

KW - prevention of mother-to-child transmission

UR - http://www.scopus.com/inward/record.url?scp=85021279667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021279667&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001569

DO - 10.1097/QAD.0000000000001569

M3 - Article

C2 - 28746086

AN - SCOPUS:85021279667

VL - 31

SP - 1885

EP - 1889

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -